You are here

  • Home
  • Archive
  • Volume 8, Issue 6
  • Overweight and obesity management strategies in survivors of paediatric acute lymphoblastic leukaemia: a systematic review protocol

Article Text

Article menu

Download PDFPDF

XML
Diabetes and endocrinology
Protocol
Overweight and obesity management strategies in survivors of paediatric acute lymphoblastic leukaemia: a systematic review protocol
  1. Salma Ladhani1,2,
  2. Brianna Empringham1,2,
  3. Kuan-Wen Wang1,2,3,
  4. Carol Portwine1,4,
  5. Laura Banfield5,
  6. Russell J de Souza3,6,
  7. Lehana Thabane3,6,7,8,9,
  8. M Constantine Samaan1,2,3,6
  1. 1 Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada
  2. 2 Division of Pediatric Endocrinology, McMaster Children’s Hospital, Hamilton, Ontario, Canada
  3. 3 Medical Sciences Graduate Program, McMaster University, Hamilton, Ontario, Canada
  4. 4 Division of Pediatric Hematology/Oncology, McMaster Children’s Hospital, Hamilton, Ontario, Canada
  5. 5 Health Sciences Library, McMaster University, Hamilton, Ontario, Canada
  6. 6 Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
  7. 7 Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada
  8. 8 Centre for Evaluation of Medicines, St. Joseph’s Health Care, Hamilton, Ontario, Canada
  9. 9 Biostatistics Unit, St Joseph’s Healthcare, Hamilton, Ontario, Canada
  1. Correspondence to Dr M Constantine Samaan; samaanc{at}mcmaster.ca

Abstract

Introduction Acute lymphoblastic leukaemia is the most common paediatric cancer. Survivors of childhood acute lymphoblastic leukaemia (SALL) are at risk of obesity and related cardiometabolic diseases including type 2 diabetes, hypertension, stroke and cardiovascular events. Therefore, it is important to address obesity in this population as this may help mitigate future cardiometabolic comorbidities. In this systematic review, we aim to assess current treatment strategies including lifestyle interventions, pharmacotherapy and bariatric surgery to manage overweight and obesity in SALL.

Methods and analysis We will search the following databases for primary studies: CINAHL, SPORTDiscus, EMBASE, MEDLINE, PsycINFO, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews. In addition, unpublished primary studies will be searched in ClinicalTrials.gov as well as conference proceedings, presentations, abstracts, editorials and ProQuest Dissertations and Theses A&I. Reviewers will perform title, abstract, and full-text screening as well as data abstraction and risk of bias assessment independently with a third reviewer to be consulted to resolve disagreements. Searches will be run and updated through May 1st, 2018. The overall quality of the evidence will be determined using the Grading of Recommendations, Assessment, Development, and Evaluation criteria for each outcome. A meta-analysis will be performed if two studies deploying similar interventions, populations, and design and outcomes are identified.

Ethics and dissemination As individual patient data will not be included, we do not require ethics approval. This review will be published in a peer-reviewed journal.

PROSPERO registration number CRD42016051031.

  • cancer survivorship
  • obesity
  • cancer aftereffects
  • lifestyle interventions
  • acute lymphoblastic leukemia

This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

https://doi.org/10.1136/bmjopen-2018-022530

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • SL and BE contributed equally.

    • Contributors MCS is the guarantor. Research question was defined by SL, BE, CP, RJdS, LT and MCS. SL, BE, KWW, CP, LB, RJdS, LT and MCS contributed to the development of search strategy and determination of the eligibility criteria. SL, BE, LB, KWW and MCS designed the data abstraction form. RJdS and LT provided methodological support for this review. SL, BE, KWW, CP and MCS wrote the first draft of the manuscript, and the final version was reviewed and approved by all authors.

    • Funding MCS was funded by the Pediatric Oncology Group of Ontario (POGO) Research Unit, and the Hamilton Health Sciences and Foundation. KWW was funded by the Ontario Graduate Scholarship Program, and the Canadian Institutes of Health Research (CIHR) Canada Graduate Scholarship-Masters. Design of the systematic review is independent of the funding agencies.

    • Competing interests None declared.

    • Patient consent Not required.

    • Provenance and peer review Not commissioned; peer reviewed for ethical and funding approval prior to submission.